Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.72 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.61 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.55 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31506335 | 1.00 | F2 (0.72) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL6557386 | 0.99 | F2 (0.73) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL19614605 | 0.92 | F2 (0.70) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14378911 | 0.91 | F2 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL4999986 | 0.89 | F2 (0.67) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL13140115 | 0.88 | F2 (0.53) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14543821 | 0.85 | F2 (1.00) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL28553185 | 0.84 | F2 (1.00) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL8000443 | 0.83 | MAOB (0.59) | F2 | |
| SCHEMBL4314299 | 0.82 | PTPRC (0.49) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015421-B1 | NEW PHENYLAMIDINE DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-03-31 | — | — | EP | claimed |
| EP-0931087-B1 | NOVEL PYRANOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2002-04-03 | — | — | EP | claimed |
| US-6197753-B1 | ANTIARTHRITIC AGENTS; ANTIHISTAMINES | BOEHRINGER INGELHEIM KG (DE) | 2001-03-06 | — | — | US | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| EP-1343769-B1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2010-08-04 | — | — | EP | disclosed |
| EP-1511737-B1 | ARYLOXIMES | MERCK PATENT GMBH (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-7563790-B2 | Pyridazine derivatives | MERCK PATENT GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7563790-B2 | Pyridazine derivatives | MERCK PATENT GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7544684-B2 | Hydrazono-malonitriles | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544684-B2 | Hydrazono-malonitriles | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-20080260817-A1 | Compositions for the Treatment of Inflammation and Pain Using a Combination of a Cox-2 Selective Inhibitor and a Ltb4 Receptor Antagonist | PFIZER INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2006011048-A1 | COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND PAIN USING A COMBINATION OF A COX-2 SELECTIVE INHIBITOR AND A LTB4 RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003104205-A1 | ARYLOXIMES | MERCK PATENT GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003039548-A1 | HYDRAZONO-MALONITRILES | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037349-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2003-05-08 | — | — | WO | disclosed |
| EP-0931087-B1 | NOVEL PYRANOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2002-04-03 | — | — | EP | disclosed |
| US-6197753-B1 | ANTIARTHRITIC AGENTS; ANTIHISTAMINES | BOEHRINGER INGELHEIM KG (DE) | 2001-03-06 | — | — | US | disclosed |
| EP-0931087-A1 | NOVEL PYRANOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998011119-A1 | NOVEL PYRANOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | F2 3934/4885PRSS1 2826/4885PRSS2 2091/4885 |
| US-20080260817-A1 | Compositions for the Treatment of Inflammation and Pain Using a Combination of a Cox-2 Selective Inhibitor and a Ltb4 Receptor Antagonist | LTB4R2, LTB4R, LTC4S | F2 382/4885PRSS1 417/4885PRSS2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.